DermaLive Injection — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

DermaLive is a semi-permanent hybrid dermal filler manufactured by Hyal Pharmaceutical Corporation, composed of a biphasic matrix combining cross-linked hyaluronic acid (HA) gel with 40–60 micron acrylic hydrogel microspheres (Hydroscryl). The HA component provides immediate volumisation and hydration upon injection, while the acrylic hydrogel microspheres act as a biostimulatory scaffold — triggering fibroblast activity, collagen deposition, and neovascularisation over several weeks as the HA is gradually absorbed. This dual-action mechanism creates both immediate and long-lasting augmentation. DermaLive is classified as a semi-permanent filler because the acrylic microspheres are non-biodegradable and persist indefinitely, while the HA carrier degrades over several months. It is distinct from standard HA fillers (Juvederm, Restylane) which are fully reversible with hyaluronidase and last 6–18 months. DermaLive is typically injected into the deep dermis or subcutaneous layer by trained aesthetic practitioners or plastic surgeons. Careful patient selection and injection technique are paramount given the permanent nature of the microsphere component. DermaLive is classified as a semi-permanent filler and requires careful patient selection due to the non-biodegradable component, which cannot be dissolved if adverse events occur. It is administered exclusively by experienced aesthetic physicians in medically supervised settings with access to granuloma treatment protocols.

DermaLive is indicated for adults with moderate-to-deep facial volume loss seeking longer-lasting correction than standard temporary HA fillers. Specific indications include deep nasolabial folds, marionette lines, cheek hollowing and mid-face volume deficiency, and lip border definition in patients who understand and accept the semi-permanent nature of treatment. Ideal candidates are medically fit adults with realistic expectations who have previously tolerated temporary filler treatments without adverse reactions, demonstrating predictable anatomical responses. Absolute contraindications include autoimmune disease (lupus, rheumatoid arthritis, scleroderma — risk of excessive inflammatory response), active facial or systemic infection, pregnancy and breastfeeding, blood clotting disorders or current anticoagulant therapy, history of keloid or hypertrophic scarring (increased risk of granuloma formation), and current or recent immunosuppressive therapy. DermaLive is not recommended for lip body augmentation, areas with thin overlying skin (periorbital, infraorbital hollow), or patients seeking reversible treatment. Patients with prior permanent fillers in the same area should disclose this history. Caution is advised in patients with implants (breast, facial) in adjacent regions. A mandatory cooling-off period of at least 14 days is recommended between consultation and treatment.

The patient attends a pre-treatment consultation at which medical history is taken, facial anatomy assessed, treatment goals discussed, informed consent obtained, and before photographs taken. The treatment area is cleansed and a topical anaesthetic cream (EMLA or LMX4) is applied for 30–45 minutes prior to injection. Some practitioners augment topical anaesthesia with a local nerve block (infraorbital, mental, or dental block) for improved patient comfort. Using a fine 27–30 gauge needle or blunt-tipped microcannula, DermaLive is injected into the deep dermis (for wrinkle correction) or subcutaneous layer (for volumisation) using linear threading, serial puncture, or fanning techniques. Injection depth is critical — superficial placement risks nodule formation and visibility. Total volume injected is 1–3 mL depending on the treatment area. Immediate post-injection massage moulds the product and ensures even distribution. The HA carrier integrates within 1–2 weeks; the microspheres stimulate collagen deposition over 4–8 weeks, with the final result visible at 4–8 weeks. Touch-up injections may be performed at 4 weeks if needed. Procedure duration is 30–45 minutes. The total appointment takes 30–60 minutes. A review at 4–6 weeks assesses the result and determines whether a conservative top-up is required; overfilling should be strictly avoided as correction of the permanent component requires surgical excision if complications arise.

DermaLive's primary benefit over standard HA fillers is duration: the non-biodegradable acrylic microspheres provide structural support lasting 2–5 years or longer in many patients — compared to 6–18 months for standard HA products. This significantly reduces the number of treatment sessions required over time, improving long-term cost-effectiveness. The biostimulatory microspheres promote endogenous collagen production, potentially improving skin quality beyond the filler effect. Patients experience immediate volume correction on the day of injection due to the HA carrier. Clinical satisfaction rates of approximately 80% are reported in published aesthetic medicine case series. For patients who have previously undergone multiple HA filler sessions with satisfactory results and seek a more durable solution, DermaLive offers a step-up treatment. Cost per session in India ranges from approximately INR 15,000–40,000 (USD 180–480), compared to USD 800–2,500 in Western markets for comparable semi-permanent fillers. The treatment is minimally invasive and requires no anaesthesia beyond topical cream, with immediate return to social activities in most cases.

The permanent nature of the acrylic microsphere component distinguishes DermaLive's risk profile from standard temporary fillers and demands careful patient selection. Granuloma formation — a chronic foreign body inflammatory reaction — is the most serious complication and can occur months to years after injection. Granulomas present as firm, tender nodules and are difficult to treat: intralesional corticosteroid injections (triamcinolone 5–10 mg/mL) are first-line, often combined with 5-fluorouracil; refractory cases may require surgical excision. Unlike HA fillers, the microsphere component cannot be dissolved with hyaluronidase — only the HA carrier is reversible. Intravascular injection causing skin necrosis or visual complications is the most serious acute complication across all filler types — experienced injectors minimise this risk by aspiration, low injection pressure, and blunt cannula technique. Immediate complications include bruising (20–30%), mild swelling (most patients for 3–7 days), and visible nodularity if placed too superficially (requires massage or review). Tyndall effect (bluish discoloration) can occur with superficial injection. Infection (cellulitis or abscess) requires prompt antibiotic treatment. Late migration is possible, though less common than with earlier generation permanent fillers.

Immediately after injection, the treated areas show mild redness, swelling, and possible bruising — most prominent at 48–72 hours and resolving over 3–7 days. Ice packs applied intermittently for the first 24 hours reduce swelling and bruising. Paracetamol is recommended for discomfort; NSAIDs and aspirin are avoided for 24–48 hours pre- and post-procedure to minimise bruising. Patients are instructed to avoid alcohol, vigorous exercise, saunas, sun exposure, and extreme temperatures for 24–48 hours to minimise swelling. Gentle upward massage as directed by the injector helps mould the product in the first 24 hours. Avoiding significant facial manipulation for the first week allows the product to settle. Make-up may be applied after 24 hours once any puncture sites have closed. The final result is assessed at 4–6 weeks — at this appointment, the injector determines whether a top-up session is appropriate. Patients must be counselled that any nodule, firmness, or asymmetry developing weeks to months after treatment should be reported promptly for early intervention before granuloma becomes established. Annual follow-up with the treating practitioner is recommended given the semi-permanent nature of the treatment.